OBD's listing on The London Stock Exchange published widely in the media.


Oxford University biotech firm heads for float on AIM - The Daily Telegraph

Oxford BioDynamics float sparks payout for university - Evening Standard

Oxford BioDynamics to list on London's junior market - Reuters

Oxford BioDynamics placing has raised gross proceeds £20m - Bloomberg Headlines

Oxford BioDynamics Plans AIM listing, raises GBP20 million to expand - Wall Street Journal/Dow Jones

Oxford University biotech spin-off to float on AIM - Proactive Investor

Oxford BioDynamics raises GBP7.1 million ahead of AIM Admission - TD Direct Investing

Oxford BioDynamics applies to trade on AIM, completes oversubscribed placing - Mergermarket

Oxford BioDynamics to float on London's AIM market on 6 December - Mergermarket

Details revealed about biotechnology firm float - Insider Media

Oxford BioDynamics raises GBP7.1 million ahead of AIM admission - Alliance News

Oxford BioDynamics aims for $25m flotation - Global University Venturing

Oxford BioDynamics is planning an IPO - ACQ5


The Atlantic publishes "Genes Are Overrated". This article points to higher order genome organisation.

Genes Are Overrated. Higher order genome conformation studied by EpiSwitch™ technology are growing trends in understanding genetics and genomics.